Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.46 USD
Change Today +0.27 / 1.22%
Volume 301.6K
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

bellicum pharmaceuticals inc (BLCM) Snapshot

Open
$22.27
Previous Close
$22.19
Day High
$23.05
Day Low
$22.09
52 Week High
01/12/15 - $33.63
52 Week Low
12/23/14 - $18.20
Market Cap
592.5M
Average Volume 10 Days
537.8K
EPS TTM
$-22.84
Shares Outstanding
26.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BELLICUM PHARMACEUTICALS INC (BLCM)

Related News

No related news articles were found.

bellicum pharmaceuticals inc (BLCM) Related Businessweek News

No Related Businessweek News Found

bellicum pharmaceuticals inc (BLCM) Details

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. The company’s preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

35 Employees
Last Reported Date: 03/20/15
Founded in 2004

bellicum pharmaceuticals inc (BLCM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $350.0K
Co-Founder, Chief Technology Officer, Chief M...
Total Annual Compensation: $250.0K
Chief Operating Officer and Senior Vice Presi...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2013.

bellicum pharmaceuticals inc (BLCM) Key Developments

Bellicum Pharmaceuticals, Inc. Reports Unaudited Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014

Bellicum Pharmaceuticals, Inc. reported unaudited financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, grant revenues were $0.02 million against $0.8 million last year. Operating loss was $49.4 million against $2.5 million last year. Net loss attributable to common shareholders was $74.3 million or $18.99 per basic and diluted share against $2.9 million or $1.68 per basic and diluted share last year. For the year, grant revenues were $1.8 million against $1.9 million last year. Operating loss was $57.8 million against $7.9 million last year. Net loss attributable to common shareholders was $85.4 million or $34.04 per basic and diluted share against $9.1 million or $5.25 per basic and diluted share last year. The higher net loss amounts for the 2014 periods were due primarily to a charge of $43.2 million incurred in the fourth quarter of 2014 in conjunction with the ARIAD license restructure transaction and a non-cash accounting charge of $24.4 million recorded for the change in fair value of warrants that were exercised in conjunction with Bellicum’s December IPO, of which $23.2 million was a fourth quarter expense.

Bellicum Pharmaceuticals, Inc. to Report Q4, 2014 Results on Mar 11, 2015

Bellicum Pharmaceuticals, Inc. announced that they will report Q4, 2014 results After-Market on Mar 11, 2015

Bellicum Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 11, 2015

Bellicum Pharmaceuticals, Inc., Q4 2014 Earnings Call, Mar 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLCM:US $22.46 USD +0.27

BLCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BLCM.
View Industry Companies
 

Industry Analysis

BLCM

Industry Average

Valuation BLCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.4x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 225.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLICUM PHARMACEUTICALS INC, please visit www.bellicum.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.